Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies after completing Phase 1 clinical trials in healthy volunteers. The company reported that the therapy demonstrated a favorable safety profile and was generally well tolerated, supporting the move to Phase 2 trials in people living with multiple sclerosis.
In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for the planned Phase 2 clinical trial. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. To strengthen operational support for the program, Quantum BioPharma is planning a partnership with Allucent and engaging neurological specialists.
Multiple sclerosis is a chronic disease that affects the central nervous system, where the immune system attacks the protective myelin sheath covering nerve fibers, leading to communication problems between the brain and the rest of the body. Current treatments primarily focus on modulating the immune system to reduce attacks, but they do not reverse existing damage. LUCID-MS is designed to target demyelination and protect or restore myelin integrity, potentially addressing the underlying cause of disability progression.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also has a portfolio of other assets targeting neurodegenerative and metabolic disorders and alcohol misuse disorders.
Quantum BioPharma retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC product unbuzzd, and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For more information on the full article discussing this development, visit https://ibn.fm/AUhNl.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials.